Alumis
ALMS | NASDAQ
$5.14
-$0.46 (-8.21%)
At close: Nov 16, 2026, 4:00 PM ET
$5.05
-$0.09 (-1.75%)
After-hours:
Nov 16, 2026, 7:57 PM ET
Alumis Company Profile
Company profile explainedCompany Profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Martin Babler | President, Chief Executive Officer & Chairman |
| John R. Schroer | Chief Financial Officer |
| Sanam Pangali | Chief Legal Officer & Corporate Secretary |
| Claire Langrish | Senior Vice President & Head of Immunology and Translational Science |
| David Goldstein | Chief Scientific Officer |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development |
| Kolbot By | Senior Vice President & Head of Technical Operations |
| Mark Bradley | Chief Development Officer |
| Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader |
| Roy C. Hardiman | Chief Business & Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 09, 2026 | 4 | Filing |
| Sep 01, 2026 | 8-K | Current Report |
| Aug 17, 2026 | SC 13D | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
Alumis
| Country | United States |
| IPO Date | Jun 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 237 |
| CEO | Martin Babler |
Contact Details
280 East Grand Avenue South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | ALMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001847367 |
| CUSIP Number | 022307102 |
| ISIN Number | US0223071020 |
| SIC Code | 2834 |
Recent News
- 2 months ago / seekingalpha.comAlumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / globenewswire.comAlumis to Participate in Upcoming September Investor Conferences
- 3 months ago / seekingalpha.comAlumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
- 3 months ago / seekingalpha.comAlumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
- 3 months ago / marketbeat.comAlumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
- 3 months ago / reuters.comAlumis eyes late-stage lupus study despite trial miss
- 3 months ago / globenewswire.comAlumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
- 3 months ago / globenewswire.comAlumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
- 3 months ago / zacks.com4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
- 3 months ago / benzinga.comAlumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Add to Watchlist
Select watchlists to add or remove ALMS